LEADER 03495nam 22005775 450 001 9911049063503321 005 20260102120855.0 010 $a3-031-89319-0 024 7 $a10.1007/978-3-031-89319-3 035 $a(CKB)44769046300041 035 $a(MiAaPQ)EBC32470856 035 $a(Au-PeEL)EBL32470856 035 $a(DE-He213)978-3-031-89319-3 035 $a(EXLCZ)9944769046300041 100 $a20260102d2026 u| 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAntibody Drug Conjugates $eDesign, Discovery, and Development /$fedited by Hovhannes J. Gukasyan, Ashutosh Kulkarni 205 $a1st ed. 2026. 210 1$aCham :$cSpringer Nature Switzerland :$cImprint: Springer,$d2026. 215 $a1 online resource (306 pages) 225 1 $aAAPS Advances in the Pharmaceutical Sciences Series,$x2210-738X ;$v52 311 08$a3-031-89318-2 327 $aCommercialized ADCs: A Market Snapshot for Exemplification -- Application of ADCs to Therapeutic Areas Outside of Oncology -- Regulatory framework for the manufacturing and marketing of ADCs -- Conjugation Chemistry and Chemical Design for the Discovery and Development of Antibody Drug Conjugates -- Clinical Pharmacology Considerations in Antibody-Drug Conjugates Development -- Bioanalytical Methodologies for Pharmacokinetic Characterization of Antibody Drug Conjugates -- Toxicology Considerations on Antibody-Drug Conjugate Discovery and Development -- Considerations for Antibody Drug Conjugate Design Stability and Formulation. 330 $aThis volume provides a comprehensive recapitulation of structure-activity relationship (SAR) from a mechanism of action point of view for this unique therapeutic modality, in a largely disease agnostic manner. From a disease biology and pharmacology perspective, the cellular target and drug-conjugate selection, considerations on liker -chemistry and -antibody ratio, and formulation science and technology, to get from bench to bedside (i.e. from a laboratory to the systemic circulation in a patient). The book also provides an understanding around target binding and drug/"payload" release mechanisms. Furthermore, pharmacokinetic and safety pharmacological aspects from a regulatory and clinical perspective are discussed, along with current chemistry, manufacturing, controls guidance and emerging novel delivery devices or technologies. The key differentiation in Antibody Drug Conjugates is the clinical and development discussion, that offers pragmatic considerations in medical product development, IP, regulatory considerations, among others. Furthermore, we discuss the topic as a platform, in a disease agnostic manner. 410 0$aAAPS Advances in the Pharmaceutical Sciences Series,$x2210-738X ;$v52 606 $aPharmacology 606 $aPharmacy 606 $aPharmaceutical chemistry 606 $aPharmacology 606 $aPharmacy 606 $aPharmaceutics 615 0$aPharmacology. 615 0$aPharmacy. 615 0$aPharmaceutical chemistry. 615 14$aPharmacology. 615 24$aPharmacy. 615 24$aPharmaceutics. 676 $a615.36 700 $aGukasyan$b Hovhannes J$01885824 701 $aGukasyan$01885825 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9911049063503321 996 $aAntibody Drug Conjugates$94521177 997 $aUNINA